How to buy Cleveland BioLabs stock (CBLI)

Cleveland BioLabs is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 18 staff and has a trailing 12-month revenue of around $106,900.

Our top picks for where to buy Cleveland BioLabs stock

Buy Cleveland BioLabs stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cleveland BioLabs stock price (NASDAQ: CBLI)

Use our graph to track the performance of CBLI stocks over time.

Cleveland BioLabs shares at a glance

• Key figures

Information last updated 2021-12-26.

52-week range	$0.00 - $0.00
50-day moving average more info button	$3.62
200-day moving average more info button	$3.62
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.74

Is it a good time to buy Cleveland BioLabs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cleveland BioLabs financials

Revenue TTM	$106,900
Gross profit TTM	$-428,128
Return on assets TTM	-20.33%
Return on equity TTM	-31.86%
Profit margin	0%
Book value	$0.60
Market Capitalization more info button	$49.1 million

TTM: trailing 12 months

Cleveland BioLabs share dividends

We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.

Have Cleveland BioLabs's shares ever split?

Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.

Cleveland BioLabs share price volatility

Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.6837. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).

Cleveland BioLabs overview

Cytocom, Inc. , a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.

Frequently asked questions

null
What percentage of Cleveland BioLabs is owned by insiders or institutions?
Currently 52.548% of Cleveland BioLabs shares are held by insiders and 4.774% by institutions. How many people work for Cleveland BioLabs?
Latest data suggests 18 work at Cleveland BioLabs. When does the fiscal year end for Cleveland BioLabs?
Cleveland BioLabs's fiscal year ends in December. Where is Cleveland BioLabs based?
Cleveland BioLabs's address is: 2537 Research Boulevard, Fort Collins, CO, United States, 80526 What is Cleveland BioLabs's ISIN number?
Cleveland BioLabs's international securities identification number is: US8575611046 What is Cleveland BioLabs's CUSIP number?
Cleveland BioLabs's Committee on Uniform Securities Identification Procedures number is: 185860103